In this edition: Biohacking in Montana, ways to track your risk of falling and the Medicare pullback

Montana aims to become biohacking hub. State legislators have backed "Right to Try" measures designed to ease access to therapies not approved by the Food and Drug Administration and adopted rules to make it easier for businesses to profit from selling experimental drugs, therapies or devices.

Medicare recipients must wait for price relief—if they get it at all. The One Big Beautiful Bill Act will cost Medicare billions in missed savings by delaying price negotiations for some of the biggest-selling drugs in the world, including Merck’s cancer drug Keytruda. Other drugs are exempted from negotiotions entirely.

Trump administration blocks funding for CDC health programs. The White House Office of Management and Budget issued the directions in a footnote on an appropriations memo this past week, blocking funding already approved by Congress for programs aimed at conditions such as diabetes, chronic kidney disease and tobacco use.

Seven ways to track your risk of falling. Medical experts say that, beginning at age 65, everyone should be screened to determine their risk level. Tools such as vital-sign monitors, gait sensors and smart pill dispensers can help, even if you are at low risk.

A turning point in colon cancer. More people aged 45 to 49 are getting screened for colorectal cancer, after recent medical guidelines lowered the screening age for those at average risk. As a result, the disease is being caught sooner, when it is more curable and the treatment is less grueling.

Strava’s CEO has a new way to improve your workouts. The company recently bought Runna and The Breakaway, two apps that generate bespoke AI plans for more serious training. CEO Michael Martin hopes the new "coach" will convince more of Strava's 150 million users to pay for a premium subscription. 

The Medicare pullback is here. Many seniors enjoy the perks that come with Medicare Advantage—like dental coverage and free gym memberships. But insurers are planning to scale back benefits, trim plans and exit from markets. Investors are cheering.

Stocks shrug off Trump drug-price letters. Pharmaceutical makers were largely unshaken by the president's latest demands to lower drug prices. Industry observers said the new measures, laid out in letters to 17 companies, would either have modest impact or face legal challenges.

Novo Nordisk's Wegovy sales surge. Lilly shares plunge. Second-quarter sales of Novo Nordisk's weight-loss drug Wegovy soared 67% over the previous year, despite U.S. patients using generic versions. Eli Lilly shares plunged about 14% Thursday after less-than-stellar results of a new study of an experimental anti-obesity pill that is expected to become a blockbuster.

This newsletter was compiled by the WSJ’s Health & Science team. Follow us on X @WSJHealth and @WSJScience. Email us by replying to this newsletter.